Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
Sponsor: Hong Wu
Summary
This study evaluates a novel "Dual-Conversion" strategy (mechanical volume conversion via LVD plus biological conversion via cTACE, Tislelizumab, and Lenvatinib) for patients with initially unresectable right-sided hepatocellular carcinoma (HCC). The primary goal is to assess the rate of successful conversion to R0 resection and the safety profile of this multi-modal approach.
Official title: A Prospective, Single-Center, Single-Arm Trial to Validate the Safety and Efficacy of "Dual-Conversion" Therapy With Liver Venous Deprivation (LVD), Conventional Transarterial Chemoembolization (cTACE), Tislelizumab, and Lenvatinib for Initially Unresectable Hepatocellular Carcinoma in the Right Liver.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-04-01
Completion Date
2028-06-30
Last Updated
2026-03-18
Healthy Volunteers
No
Interventions
Liver Venous Deprivation (LVD)
Simultaneous embolization of the right portal vein and right hepatic vein to induce FLR hypertrophy.
Conventional Transarterial Chemoembolization(C-TACE)
Conventional TACE performed using Lipiodol and chemotherapy agents (Epirubicin/Oxaliplatin)
Tislelizumab combined with Lenvatinib
Tislelizumab 200 mg administered intravenously every 3 weeks (Q3W) + 8 mg (for weight \<60 kg) or 12 mg (for weight ≥60 kg) orally once daily (QD)
Locations (1)
West China Hospital, Sichuan University
Chengdu, Sichuan, China